| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| | 10-K | 10-K | 8-K | S-1 |
| Revenues: |
| United States | 4.8 | 3.3 | | |
| United Kingdom | 0.2 | 0.5 | | |
| Denmark | 0.3 | 0.4 | | |
| Total revenues | 5.4 | 4.2 | 4.2 | |
| Revenue growth [+] | 28.2% | -0.4% | | |
| United States | 45.5% | | | |
| United Kingdom | -59.7% | | | |
| Denmark | -10.7% | | | |
| Cost of goods sold | 4.2 | 2.0 | 0.0 | |
| Gross profit | 1.2 | 2.2 | 4.2 | |
| Gross margin | 21.9% | 52.2% | 100.0% | |
| Selling, general and administrative | 30.1 | 22.9 | 5.5 | |
| Research and development | 8.0 | 6.5 | 2.9 | |
| Other operating expenses | -12.1 | 0.3 | 0.5 | |
| EBITDA [+] | -24.5 | -27.4 | 160.3 | |
| EBITDA growth | -10.6% | -117.1% | | |
| EBITDA margin | -455.7% | -653.6% | 3807.8% | |
| Depreciation | 0.2 | 0.0 | 165.0 | |
| EBITA | -24.6 | -27.4 | -4.7 | |
| EBITA margin | -458.5% | -654.3% | -111.3% | |
| Amortization of intangibles | 0.1 | 0.1 | | |
| EBIT [+] | -24.8 | -27.6 | -4.7 | |
| EBIT growth | -10.1% | 487.9% | | |
| EBIT margin | -461.1% | -657.6% | -111.3% | |
| Non-recurring items | 12.1 | -0.3 | | |
| Interest expense, net [+] | -0.1 | 0.6 | 0.3 | |
| Interest expense | | 0.6 | 0.3 | |
| Interest income | 0.1 | | | |
| Other income (expense), net [+] | 12.2 | -46.8 | 0.1 | |
| Unrealized gain/loss on derivatives | 12.1 | -0.3 | | |
| Change in fair value of warrants | 12.0 | -0.3 | | |
| Other | 12.4 | -47.4 | -0.2 | |
| Pre-tax income | -24.6 | -74.6 | -4.9 | |
| Income taxes | 0.0 | 0.0 | 0.0 | |
| Minority interest | -0.5 | -2.1 | | |
| Net income | -24.9 | -72.8 | -4.9 | |
| Net margin | -463.9% | -1738.2% | -116.0% | |
| |
| Basic EPS [+] | ($1.19) | ($4.37) | | |
| Growth | -72.8% | | | |
| Diluted EPS [+] | ($1.19) | ($4.37) | | |
| Growth | -72.8% | | | |
| |
| Shares outstanding (basic) [+] | 21.0 | 16.7 | | |
| Growth | 25.9% | | | |
| Shares outstanding (diluted) [+] | 21.0 | 16.7 | | |
| Growth | 25.9% | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |